Publications

Detailed Information

Prognostic factors related to photodynamic therapy for central serous chorioretinopathy

DC Field Value Language
dc.contributor.authorMoon, Jun Woong-
dc.contributor.authorYu, Hyeong Gon-
dc.contributor.authorKim, Tae Wan-
dc.contributor.authorKim, Hyung Chan-
dc.contributor.authorChung, Hum-
dc.date.accessioned2012-06-29T06:09:36Z-
dc.date.available2012-06-29T06:09:36Z-
dc.date.issued2009-10-
dc.identifier.citationGRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY; Vol.247 10; 1315-1323ko_KR
dc.identifier.issn0721-832X-
dc.identifier.urihttps://hdl.handle.net/10371/77954-
dc.description.abstractTo investigate the effects and prognostic factors related to photodynamic therapy (PDT) for central serous chorioretinopathy (CSC). Retrospective medical record reviewing of consecutive CSC patients (chronic or persistent typical CSC) treated with conventional PDT (full-dose verteporfin, laser (689 nm) delivery for 83 s, total light energy of 50 J/cm(2)) was performed. Besides overall anatomic and functional outcomes, the prognostic influences of various baseline factors (sex, age, duration of symptoms, presence of focal leak and pigment epithelial detachment (PED), SRF size, confluent RPE atrophy, PDT spot size), disintegrity of the junction between foveal outer and inner photoreceptor layer (OS-IS) after resolution, and post-treatment RPE changes on outcomes were evaluated. Forty patients (41 eyes) were included. Anatomic success, defined as complete resolution of serous fluid on optical coherence tomography performed 4-6 weeks after PDT, was achieved in 87.8% of eyes, and visual acuity improved significantly (0.19 +/- 0.24 lines). Visual acuity had improved more than one line in 46.3% of the patients and decreased more than one line in 14.6% of patients at the 1-month follow-up visit. Prolonged symptom duration (> 9 months), PED, confluent RPE atrophy, foveal OS-IS disintegrity, and post-PDT RPE changes were associated significantly with visual loss of more than three lines and foveal atrophy. Central macular thickness was significantly reduced in patients treated with PDT compared to those treated with focal laser. PDT for CSC was effective with regard to anatomic and functional outcomes. However, visual improvement may be limited in patients with prolonged symptom duration, baseline confluent RPE atrophy, foveal OS-IS disintegrity, or progression of RPE atrophy after PDT and the risk of PDT-induced foveal injury should be considered.ko_KR
dc.language.isoenko_KR
dc.publisherSPRINGERko_KR
dc.subjectCentral serous chorioretinopathyko_KR
dc.subjectPhotodynamic therapyko_KR
dc.titlePrognostic factors related to photodynamic therapy for central serous chorioretinopathyko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor문준웅-
dc.contributor.AlternativeAuthor유형곤-
dc.contributor.AlternativeAuthor김태완-
dc.contributor.AlternativeAuthor김형찬-
dc.contributor.AlternativeAuthor정흠-
dc.identifier.doi10.1007/s00417-009-1104-8-
dc.citation.journaltitleGRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY-
dc.description.citedreferenceChan WM, 2008, OPHTHALMOLOGY, V115, P1756, DOI 10.1016/j.ophtha.2008.04.014-
dc.description.citedreferenceChan WM, 2008, RETINA-J RET VIT DIS, V28, P85-
dc.description.citedreferenceShe HC, 2007, INVEST OPHTH VIS SCI, V48, P2268, DOI 10.1167/iovs.06-0979-
dc.description.citedreferenceCHUNG SE, 2007, J KOREAN OPHTHALMOL, V48, P279-
dc.description.citedreferenceSONG MH, 2007, J KOREAN OPHTHALMOL, V48, P1048, DOI DOI 10.3341/JK0S.2007.48.8.1048-1056-
dc.description.citedreferenceLEEM HS, 2007, J KOREAN OPHTHALMOL, V48, P1369-
dc.description.citedreferenceLai TYY, 2006, BRIT J OPHTHALMOL, V90, P869, DOI 10.1136/bjo.2006.090282-
dc.description.citedreferenceOber MD, 2005, OPHTHALMOLOGY, V112, P2088, DOI 10.1016/j.ophtha.2005.06.026-
dc.description.citedreferenceEandi CM, 2005, RETINA-J RET VIT DIS, V25, P417-
dc.description.citedreferenceOlivier S, 2005, CAN J OPHTHALMOL, V40, P214-
dc.description.citedreferencePiccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037-
dc.description.citedreferenceTaban M, 2004, AM J OPHTHALMOL, V137, P1073, DOI 10.1016/j.ajo.2004.01.043-
dc.description.citedreferenceChan WM, 2003, BRIT J OPHTHALMOL, V87, P1453-
dc.description.citedreferencePiccolino FC, 2003, RETINA-J RET VIT DIS, V23, P752-
dc.description.citedreferenceYannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288-
dc.description.citedreferenceParodi MB, 2003, RETINA-J RET VIT DIS, V23, P235-
dc.description.citedreferenceIida T, 2003, RETINA-J RET VIT DIS, V23, P1-
dc.description.citedreferenceWang MSM, 2002, AM J OPHTHALMOL, V133, P787-
dc.description.citedreferenceSchmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830-
dc.description.citedreferenceLoo RH, 2002, RETINA-J RET VIT DIS, V22, P19-
dc.description.citedreferenceBandello F, 2001, J FR OPHTALMOL, V24, P448-
dc.description.citedreferenceReinke MH, 1999, OPHTHALMOLOGY, V106, P1915-
dc.description.citedreferenceDelPriore LV, 1996, AM J OPHTHALMOL, V122, P629-
dc.description.citedreferenceSpaide RF, 1996, RETINA-J RET VIT DIS, V16, P203-
dc.description.citedreferencePrunte C, 1996, AM J OPHTHALMOL, V121, P26-
dc.description.citedreferenceDELPRIORE LV, 1995, ARCH OPHTHALMOL-CHIC, V113, P939-
dc.description.citedreferenceGUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057-
dc.description.citedreferenceYANNUZZI LA, 1992, EUR J OPHTHALMOL, V2, P103-
dc.description.citedreferenceFICKER L, 1988, BRIT J OPHTHALMOL, V72, P829-
dc.description.citedreferenceKLEIN ML, 1974, ARCH OPHTHALMOL-CHIC, V91, P247-
dc.description.citedreferenceGASS JDM, 1967, AM J OPHTHALMOL, V63, P587-
dc.description.tc9-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share